InsiderTrades

Form 4 for RPRX Royalty Pharma plc

Accepted 2025-05-20 00:00:00 ET · period of report 2025-05-16 · accession 0001802768-25-000063 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2025-05-20 2025-05-16 RPRX Legorreta Pablo G. CEO, COB, Dir J - Other $0.00 +530.3K 882.5K +151% $0
DI 2025-05-20 2025-05-16 RPRX Legorreta Pablo G. CEO, COB, Dir J - Other $0.00 +857.1K 857.1K New $0
DI 2025-05-20 2025-05-16 RPRX Legorreta Pablo G. CEO, COB, Dir A - Grant $0.00 +13.36M 13.36M New $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Class A Ordinary Shares 2025-05-16 J A 530,348 $0.00 882,495 D — —
2 Derivative Option (Right to Buy) 2025-05-16 J A 857,138 $0.00 857,138 I By PL RPH Holdings, LLC $0.00 · — to — 857,138 Class A Ordinary Shares (F4) Represents the Reporting Person's right to acquire certain Class E Shares held by other employees of the Issuer and its subsidiaries in the event such Class E Shares are forfeited by such employee. (F3) Each Class E share will vest in installments over a 5-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis, and there is no expiration date for such conversion.
3 Derivative Class E Ordinary Shares 2025-05-16 A A 13,356,742 $0.00 13,356,742 I By PL RPH Holdings, LLC $0.00 · — to — 13,356,742 Class A Ordinary Shares (F2) Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class E ordinary shares ("Class E Shares") of Royalty Pharma Holdings Ltd ("RPH") in connection with the consummation of the transactions contemplated by the Membership Interests Purchase Agreement, dated as of January 10, 2025 (as may be amended from time to time, the "Purchase Agreement") between RPH, Royalty Pharma, LLC, RP Management, LLC, the Issuer and certain other parties thereto. (F3) Each Class E share will vest in installments over a 5-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis, and there is no expiration date for such conversion.